logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

What We Expect to Hear at the Regenxbio Conference Call Today

Regenxbio Conference Call Information Regenxbio will host a conference call today, at 4:30 pm est today, November 4, 2020, to discuss its financial results for the quarter, ended September 30, 2020, and recent operational highlights. To access the live call...

Read More

November 4, 2020

0

An Important Statement to Prohost Readers

Prohost has just finished a very hard task; evaluating its best picks from the biotechnology and biopharmaceutical sectors. In this evaluation of hand-selected stocks, Prohost did not consider the negotiation between the U.S. and China a serious factor that could...

Read More

August 5, 2019

0

A Novel Immunotherapy Approach for the Treatment of COVID-19

Corvus Pharmaceuticals: FDA Granted IND Application for COVID-19 Trial The United States FDA granted approval of Corvus Pharmaceuticals ( CRVS ) investigational new drug ( IND ) application for a COVID-19 trial. Corvus announced the beginning of the Phase 1 study...

Read More

July 7, 2020

0

What We Learned from Yesterday's and Today's Stocks' Moves

What Have We Learned from the Market's Recent Stock Moves? Well. Did we learn anything from what happened in the stock market and the reversal that started near the end of yesterday and occurred today? Listening to Larry Kudlow, the...

Read More

August 6, 2019

0

Unveiled Good News About Prohost Picked Biotech Stocks

 The News Prohost Was Waiting for to Post Its Special Letter Prohost has one eye on the development-stage biotech and biopharmaceutical companies' scientific fundamentals and accomplishments as well as the financial results on the revenue-generating firms. Prohost has the second...

Read More

August 8, 2019

0

Nektar's Story Has Nothing to Do with the Efficacy Or the Value of NKTR-214

Nektar Therapeutics Story Everything was going well with Nektar Therapeutics ( NKTR ) stock during the Conference call regarding the firm’s Q2 financial results. (See the firm's press release under our Impacting News column). Following the Conference call the company...

Read More

August 9, 2019

0

The Small Firm Whose Stock Soared in Yesterday's Market

Firms' with COVID-19 Vaccines Stock Performance A look at the stock performance of the COVID-19 vaccine firms that have demonstrated early, promising and even good news regarding their prophylactic effect. The outcome was as follows:    Moderna ( MRNA )...

Read More

July 21, 2020

0

A First in Class Antibody for a Difficult to Treat Stomach Cancer and Maybe Others

Five Prime Therapeutics Antibody Plus Chemotherapy for Stomach Cancer Five Prime Therapeutics ( FPRX )  announced positive topline results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial compared mFOLFOX6 chemotherapy in combination with bemarituzumab ( bema, FPA144 ) - a first-in-class...

Read More

November 11, 2020

0

The FDA Approved Gilead Sciences CAR T Cell Product Tecartus for Adults with Relapsed or Refractory Mantle Cell Lymphoma

Gilead Sciences CAR T Cell Product Tecartus Gets FDA Approval The U.S. FDA approved Kite - Gilead Sciences ( GILD ) chimeric antigen receptor (CAR) T cell therapyTecartus™ (brexucabtagene autoleucel). Tecartus has become the first and the only approved CAR...

Read More

July 27, 2020

0

Inovio to Proceed with Phase 2 Trial of INO-4800 Vaccine Candidate for COVID-19

Inovio Announced FDA Clearance to Proceed with Trial for COVID-19 Vaccine Candidate Inovio ( INO ) announced the receipt of the U.S. FDA clearance to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800,...

Read More

November 16, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 100
  • 101
  • 102
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy